-DOCSTART- -X- O
Farnesyltransferase -X- _ O
has -X- _ O
been -X- _ O
regarded -X- _ O
as -X- _ O
a -X- _ O
promising -X- _ O
drug -X- _ O
target -X- _ O
against -X- _ O
cancer -X- _ O
as -X- _ O
it -X- _ O
is -X- _ O
critical -X- _ O
for -X- _ O
membrane -X- _ O
association -X- _ O
of -X- _ O
several -X- _ O
signal -X- _ O
transduction -X- _ O
proteins. -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
a -X- _ O
novel -X- _ O
farnesyltransferase -X- _ B-Intervention
inhibitor -X- _ I-Intervention
( -X- _ I-Intervention
IMB-1406 -X- _ I-Intervention
) -X- _ I-Intervention
was -X- _ O
identified -X- _ O
through -X- _ O
virtual -X- _ O
screening. -X- _ O
It -X- _ O
exhibits -X- _ O
stronger -X- _ O
potency -X- _ O
( -X- _ O
IC -X- _ O
( -X- _ O
50 -X- _ O
) -X- _ O
s -X- _ O
: -X- _ O
6.92–8.99 -X- _ O
μM -X- _ O
) -X- _ O
than -X- _ O
Sunitinib -X- _ B-Comparison
against -X- _ O
all -X- _ O
of -X- _ O
the -X- _ O
tested -X- _ O
cancer -X- _ B-Patient
cell -X- _ I-Patient
lines. -X- _ I-Patient
Preliminary -X- _ O
studies -X- _ O
on -X- _ O
mechanism -X- _ O
reveal -X- _ O
that -X- _ O
IMB-1406 -X- _ O
induces -X- _ O
apoptosis -X- _ O
in -X- _ O
HepG2 -X- _ O
cells -X- _ O
by -X- _ O
arresting -X- _ O
the -X- _ O
cell -X- _ O
cycle -X- _ O
at -X- _ O
the -X- _ O
S -X- _ O
phase -X- _ O
, -X- _ O
altering -X- _ O
anti- -X- _ O
and -X- _ O
pro-apoptotic -X- _ O
proteins -X- _ O
leading -X- _ O
to -X- _ O
mitochondrial -X- _ O
dysfunction -X- _ O
and -X- _ O
activation -X- _ O
of -X- _ O
caspase-3. -X- _ O
This -X- _ O
anti-tumor -X- _ B-Outcome
effect -X- _ I-Outcome
is -X- _ I-Outcome
most -X- _ I-Outcome
probably -X- _ I-Outcome
related -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
inhibition -X- _ I-Outcome
of -X- _ I-Outcome
farnesyltransferase -X- _ I-Outcome
as -X- _ I-Outcome
indicated -X- _ I-Outcome
by -X- _ I-Outcome
molecular -X- _ I-Outcome
docking. -X- _ I-Outcome
Overall -X- _ I-Outcome
, -X- _ I-Outcome
IMB-1406 -X- _ I-Outcome
is -X- _ I-Outcome
a -X- _ I-Outcome
novel -X- _ I-Outcome
lead -X- _ I-Outcome
compound -X- _ I-Outcome
with -X- _ I-Outcome
potent -X- _ I-Outcome
antitumor -X- _ I-Outcome
activity -X- _ I-Outcome
and -X- _ I-Outcome
deserves -X- _ I-Outcome
further -X- _ I-Outcome
structural -X- _ I-Outcome
modifications -X- _ I-Outcome
. -X- _ O

